Managers / Q2 2025 · view latest →
GILEAD SCIENCES, INC.
CIK 0000882095 · 333 LAKESIDE DR, FOSTER CITY, CA, 94404 · 6505743000
Reported Value
$1.3B
Q2 2025
Positions
14
Filings on Record
6
2019–present window
Filed
Aug 14, 2025
original filing
Summary
Gilead Sciences, Inc. reported $1.3B in U.S.-listed holdings across 14 positions for Q2 2025.
The portfolio is heavily concentrated: LKFT alone accounts for 36.5% of reported value.
The book was largely unchanged from Q1 2025.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 60.9% · $780M
- ADR · 36.5% · $468M
- Other · 2.6% · $33M
Quarter-over-Quarter Changes full breakdown →
Holdings — Q2 2025
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $2.1B | 6 | May 8, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $1.9B | 6 | Feb 12, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $1.8B | 9 | Nov 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $1.3B | 14 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $1.2B | 14 | May 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $1.6B | 16 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Gilead Therapeutics A1 Unlimited Co028-25083
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.